Glycemic exposure, glycemic control, and metabolic karma in diabetic complications

Advances in Chronic Kidney Disease

Volumn 21, Issue 3, 2014, Pages 311-317

  Thomas, Merlin C ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Diabetes; Diabetic nephropathy; Epigenetics; Legacy; Memory

Indexed keywords

GLUCOSE; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL OBSERVATION; DIABETES MELLITUS; EPIGENETICS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; METABOLIC KARMA; METABOLIC PARAMETERS; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; DIABETIC NEPHROPATHIES; GENETIC EPIGENESIS; GENETICS; HYPERGLYCEMIA; METABOLISM; PHYSIOLOGY;

DIABETIC NEPHROPATHIES; EPIGENESIS, GENETIC; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 84899524122     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.03.004     Document Type: Review

References (47)

1. Cooper M.E., El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 2010, 107(12):1403-1413.
2. Penno G., Solini A., Bonora E., et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2013, 36(8):2301-2310.
3. Kowluru R.A. Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression. Curr Med Chem 2013, 20(26):3226-3233.
4. Pop-Busui R., Herman W.H., Feldman E.L., et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010, 10(4):276-282.
5. Cahill G.F. Metabolic memory. N Engl J Med 1980, 302(7):396-397.
6. Bianchi C., Del Prato S. Metabolic memory and individual treatment aims in type 2 diabetes-outcome-lessons learned from large clinical trials. Rev Diabet Stud 2011, 8(3):432-440.
7. Barr E.L., Zimmet P.Z., Welborn T.A., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116(2):151-157.
8. Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841.
9. Okabe J., Orlowski C., Balcerczyk A., et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res 2012, 110(8):1067-1076.
10. Brasacchio D., Okabe J., Tikellis C., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58(5):1229-1236.
11. El-Osta A., Brasacchio D., Yao D., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205(10):2409-2417.
12. Pirola L., Balcerczyk A., Tothill R.W., et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res 2011, 21(10):1601-1615.
13. Engerman R.L., Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36(7):808-812.
14. Quadri S., Prathipati P., Jackson D.W., Jackson K.E. Hemodynamic consequences of recurrent insulin-induced hypoglycemia. Clin Exp Pharmacol Physiol 2014, 41(1):81-88.
15. Jin W.L., Azuma K., Mita T., et al. Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia 2011, 54(7):1921-1929.
16. Borg R., Kuenen J.C., Carstensen B., et al. HbA(1)(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011, 54(1):69-72.
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(14):977-986.
18. Retinopathy and nephropathy in patients with type 1 diabetes fouryears after a trial of intensive therapy. Am J Ophthalmol 2000, 129(5):704-705.
19. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342(6):381-389.
20. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003, 290(16):2159-2167.
21. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research group. Diabetes 1986, 35(5):530-545.
22. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002, 287(19):2563-2569.
23. Chalmers J., Cooper M.E. UKPDS and the legacy effect. N Engl J Med 2008, 359(15):1618-1620.
24. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
25. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359(15):1565-1576.
26. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
27. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
28. Zoungas S., Chalmers J. ADVANCE-ON: current status. Medicographia 2013, 35:61-66.
29. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591.
30. Uziel O., Singer J.A., Danicek V., et al. Telomere dynamics in arteries and mononuclear cells of diabetic patients: effect of diabetes and of glycemic control. Exp Gerontol 2007, 42(10):971-978.
31. Astrup A.S., Tarnow L., Jorsal A., et al. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia 2010, 53(1):45-48.
32. Thomas M.C. Advanced glycation end products. Contrib Nephrol 2011, 170:66-74.
33. Burns W.C., Thomas M.C. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010, 12:e17.
34. Herman-Edelstein M., Thomas M.C., Thallas-Bonke V., Saleem M., Cooper M.E., Kantharidis P. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-beta: a model for diabetic podocytopathy. Diabetes 2011, 60(6):1779-1788.
35. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339(2):69-75.
36. Sackmann H., Tran-Van T., Tack I., Hanaire-Broutin H., Tauber J.P., Ader J.L. Renal functional reserve in IDDM patients. Diabetologia 1998, 41(1):86-93.
37. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
38. Sapienza C., Lee J., Powell J., et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011, 6(1):20-28.
39. Olsen A.S., Sarras M.P., Leontovich A., Intine R.V. Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes 2012, 61(2):485-491.
40. Shi Y., Whetstine J.R. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 2007, 25(1):1-14.
41. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403(6765):41-45.
42. Miao F., Gonzalo I.G., Lanting L., Natarajan R. Invivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004, 279(17):18091-18097.
43. Miao F., Smith D.D., Zhang L., Min A., Feng W., Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008, 57(12):3189-3198.
44. Miao F., Wu X., Zhang L., Yuan Y.C., Riggs A.D., Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem 2007, 282(18):13854-13863.
45. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24(7):1266-1271.
46. Sayyed S.G., Gaikwad A.B., Lichtnekert J., et al. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrol Dial Transplant 2010, 25(6):1811-1817.
47. Kantharidis P., Wang B., Carew R.M., Lan H.Y. Diabetes complications: the microRNA perspective. Diabetes 2011, 60(7):1832-1837.